Literature DB >> 20466565

Prevalence of pulmonary hypertension in end-stage cystic fibrosis and correlation with survival.

Adriano R Tonelli1, Sebastian Fernandez-Bussy, Saba Lodhi, Olufemi A Akindipe, Robin D Carrie, Karen Hamilton, Kamal Mubarak, Maher A Baz.   

Abstract

BACKGROUND: Limited information is available about the prevalence of pulmonary hypertension diagnosed by right heart catheterization (RHC) in patients with cystic fibrosis being evaluated for lung transplantation. It is unclear whether there are factors that can predict the presence of pulmonary hypertension and whether the presence of pulmonary hypertension influences patient outcomes.
METHODS: The study included 57 unique and consecutive adult patients (33 women) with cystic fibrosis who underwent lung transplant evaluation at the University of Florida.
RESULTS: The average age at evaluation was 31.8 +/- 10 years. All patients were in New York Heart Association class III. The median (interquartile range) of mean pulmonary artery pressure (PAP) was 26 (24-30) mm Hg. Thirty-six patients (63.2%) had pulmonary hypertension (mean PAP >or= 25 mm Hg) and had a significantly higher degree of hypoxemia and oxygen requirements. Echocardiography evidenced limitations for the diagnosis of pulmonary hypertension. The 5-year mortality rate was similar in patients with or without pulmonary hypertension; however, it was higher in 7 patients identified by cluster analysis and in patients with a left ventricular ejection fraction < 55%.
CONCLUSIONS: More than half of our patients with cystic fibrosis and advanced lung disease have elevation of PAP, usually of mild degree. A lower left ventricular ejection fraction, but not the presence of pulmonary hypertension, was associated with worse outcomes. Copyright (c) 2010 International Society for Heart and Lung Transplantation. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20466565     DOI: 10.1016/j.healun.2010.04.006

Source DB:  PubMed          Journal:  J Heart Lung Transplant        ISSN: 1053-2498            Impact factor:   10.247


  13 in total

1.  Influence of pulmonary hypertension on survival in advanced lung disease.

Authors:  Don Hayes; Sylvester M Black; Joseph D Tobias; Heidi M Mansour; Bryan A Whitson
Journal:  Lung       Date:  2015-02-18       Impact factor: 2.584

Review 2.  Lung transplant referral for individuals with cystic fibrosis: Cystic Fibrosis Foundation consensus guidelines.

Authors:  Kathleen J Ramos; Patrick J Smith; Edward F McKone; Joseph M Pilewski; Amy Lucy; Sarah E Hempstead; Erin Tallarico; Albert Faro; Daniel B Rosenbluth; Alice L Gray; Jordan M Dunitz
Journal:  J Cyst Fibros       Date:  2019-03-27       Impact factor: 5.482

3.  Polysomnographic differences associated with pulmonary hypertension in patients with advanced lung disease due to cystic fibrosis.

Authors:  Don Hayes; Curt J Daniels; Stephen Kirkby; Benjamin T Kopp; Kerri L Nicholson; Ashley E Nance; Mark L Splaingard
Journal:  Lung       Date:  2014-03-27       Impact factor: 2.584

4.  Decreased right ventricular function in healthy pediatric cystic fibrosis patients versus non-cystic fibrosis patients.

Authors:  Nazire Ozcelik; Richard Shell; Melissa Holtzlander; Clifford Cua
Journal:  Pediatr Cardiol       Date:  2012-06-10       Impact factor: 1.655

5.  Pulmonary hypertension before first and second lung transplantation.

Authors:  Adriano R Tonelli; Irina Timofte; Omar A Minai; Maher Baz; Olufemi Akindipe
Journal:  Clin Transplant       Date:  2012-02-10       Impact factor: 2.863

Review 6.  Pulmonary hypertension survival effects and treatment options in cystic fibrosis.

Authors:  Adriano R Tonelli
Journal:  Curr Opin Pulm Med       Date:  2013-11       Impact factor: 3.155

7.  Use of a low-resistance compliant thoracic artificial lung in the pulmonary artery to pulmonary artery configuration.

Authors:  Christopher N Scipione; Rebecca E Schewe; Kelly L Koch; Andrew W Shaffer; Amit Iyengar; Keith E Cook
Journal:  J Thorac Cardiovasc Surg       Date:  2013-02-10       Impact factor: 5.209

8.  Hemodynamic design requirements for in-series thoracic artificial lung attachment in a model of pulmonary hypertension.

Authors:  Begum Akay; Julie A Foucher; Daniele Camboni; Kelly L Koch; Ayushi Kawatra; Keith E Cook
Journal:  ASAIO J       Date:  2012 Jul-Aug       Impact factor: 2.872

9.  Prognostic value of pre-transplant mean pulmonary arterial pressure in lung transplant recipients: a single-institution experience.

Authors:  Chi Young Kim; Ji Eun Park; Ah Young Leem; Joo Han Song; Song Yee Kim; Kyung Soo Chung; Eun Young Kim; Ji Ye Jung; Young Ae Kang; Young Sam Kim; Joon Chang; Jin Gu Lee; Hyo Chae Paik; Moo Suk Park
Journal:  J Thorac Dis       Date:  2018-03       Impact factor: 2.895

10.  Pulmonary acceleration time to optimize the timing of lung transplant in cystic fibrosis.

Authors:  Thibaud Damy; Pierre-Régis Burgel; Jean-Louis Pepin; Pierre-Yves Boelle; Claire Cracowski; Marlène Murris-Espin; Raphaele Nove-Josserand; Nathalie Stremler; Tabassome Simon; Serge Adnot; Brigitte Fauroux
Journal:  Pulm Circ       Date:  2012 Jan-Mar       Impact factor: 3.017

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.